
MicuRx completes USD25m series B financing
MicuRx Pharmaceuticals, a privately-held biopharmaceutical company developing next-generation antibiotics, has raised USD25m in series B financing. Led by BVCF, a private equity and growth fund specialising in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures. Proceeds from the series B financing


